Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Shareholders' Equity (Tables)

v3.24.1
Shareholders' Equity (Tables)
12 Months Ended
Dec. 31, 2023
Stockholders' Equity Note [Abstract]  
Schedule of Information Regarding Outstanding Warrants to Purchase Shares The following table summarizes information regarding outstanding warrants to purchase the Company’s ordinary shares as of December 31, 2023:
Issuance date   Number of
outstanding
Warrants
    Exercise
price per
warrant
 
             
January 2019     223,810     $ 0.65  
April 2019     492,308     $ 0.43  
May 2019     47,250,000     $ 0.13  
January 2020     23,838,038     $ 0.12  
February 2020     11,250,000     $ 0.05  
June 2020     61,390,260     $ 0.08  
July 2020     29,419,890     $ 0.08  
August 2021     10,500,000     $ 0.07  
December 2021     10,500,000     $ 0.07  
January 2023     409,091,100     $ 0.01  
January 2023     28,636,500     $ 0.02  
November 2023     1,219,418,700     $ 0.01  
                 
      1,852,010,606          
Schedule of Expenses Recognized Financial Statements Expenses recognized in the financial statements:
    Year ended December 31,  
    2023     2022     2021  
                   
Research and development   $ 83     $ 137     $ 200  
General and administrative     178       126       266  
      261       263       466  

 

Schedule of Fair value of Company’s Share Options Granted The fair value of the Company’s share options granted was estimated using the binomial option pricing model using the following range assumptions:
Description   2023     2022     2021  
                   
Risk-free interest rate     3.95%-3.96 %     1.41-3.08 %     1.22-1.28 %
Expected volatility     84.30%-84.76 %     83.98-84.26 %       82.40-82.43 %
Dividend yield     0 %     0 %     0 %
Contractual life (in years)     10       10       10  
Early Exercise Multiple (Suboptimal Factor)     2.5       2.5-3       3  
Schedule of Weighted Average Exercise Prices Share Options The following table lists the number of share options, their weighted average exercise prices and modification in option plans of employees, directors and consultants for the year ended December 31, 2023 and related information:
    Number of options     Weighted
average
exercise
price
    Weighted average remaining contractual terms (in years)     Aggregate intrinsic value  
                         
Outstanding at December 31, 2022     27,002,200       0.13       7.14      
   -
 
Granted     55,500,000       0.01       10      
-
 
Forfeited/expired     (25,200 )    
-
      -      
-
 
                                 
Outstanding at December 31, 2023     82,477,000       0.04       8.40      
-
 
                                 
Vested and expected to vest at December 31, 2023     82,477,000       0.04       8.40      
-
 
                                 
Exercisable at December 31, 2023     24,280,125       0.11       7.21      
-